RDIF and Stelis Biopharma partner to vaccinate 100 million with Sputnik V
The Russian Direct Investment Fund (RDIF) and Stelis Biopharma, the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against COVID-19, sufficient to vaccinate 100 million people. Sputnik V is now approved for… Read More